Plain-English translation of NCT06660667 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing , a new medication delivered as a single injection directly into the eye to treat wet age-related macular degeneration (a condition where abnormal blood vessels damage your central vision). Researchers want to find the right dose and confirm that this one-time treatment is safe and can help preserve or improve vision over time.
People with wet macular degeneration currently need repeated eye injections over months or years to control their condition. This medication aims to provide lasting benefit from just one injection, which could reduce the burden of frequent doctor visits and ongoing treatments.
You would receive one injection of the medication into your eye on Day 1. After that, you would return for regular check-ups over the next 12 months to monitor your vision and eye health. Following the first year, you would continue in an extended follow-up phase with visits through Year 5 to ensure the treatment remains safe and continues to work.
AI-generated summary from trial data · Aug 10, 2026 · Not medical advice
United States